What you'll learn in this expert session
New medications for Alzheimer’s disease mean clinicians now, more than ever, need to identify and diagnose patients early in the disease process, when these treatments are most likely to be effective. In this presentation, Dr Steph Daly and Dr Rebecca Moore, both general practitioners, discuss the importance of identifying and assessing mild cognitive impairment and determining which patients are most at risk of progressing to Alzheimer’s disease. Additionally, they address the role of blood biomarkers in this assessment and the eligibility criteria for these new medications.
About the Expert
Dr Stephanie Daly
Dr Stephanie Daly is a specialist GP in dementia. She is a fellow of the Royal Australian College of General Practitioners and has completed postgraduate training in Dementia Studies at the University of Bradford in the UK. Since moving to Australia, she has become an advocate for patients living with dementia and has facilitated her practice in becoming one of the first dementia-friendly (Dementia Australia-approved) GP surgeries in Australia
About the Expert
Dr Rebecca Moore
Dr Rebecca Moore graduated from the University of Adelaide and completed her RACGP fellowship while working as an Aviation Medical Officer in the RAAF. She has worked in general practice and urgent care in both the UK and Australia and now has a special interest in geriatric medicine. She completed a master’s degree in dementia in 2024
Course curriculum
-
1
MCI, Bio Markers and Medications
-
Summary
-
Video lecture (30 mins)
-
Quiz: test your learning (10 mins)
-
-
2
Document your CPD here
-
CPD Documentation and Reflection Activity Tool
-
-
3
Feedback
-
Please let us know your thoughts
-